Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP League, MHLW Discussing to Create Forum to Study SaMD Reimbursement
December 13, 2022
- Paper Retraction Won’t Impact Zolgensma Japan Approval, Data Deleted from Label
December 13, 2022
- Yescarta, Breyanzi Clear Panel Review for Second-Line Use
December 13, 2022
- Japan Panel Recognizes 5 More Deaths Possibly Linked to COVID Jabs, 1st for 20s
December 13, 2022
- Japan’s Diet Enacts Bill to Amend Intractable Disease Law
December 13, 2022
- Add New Evaluation Elements in Granting Launch Premiums: Expert Panel
December 12, 2022
- Market Expansion Re-Pricing Has Gone Overboard with Spillover Rule, Experts Say
December 12, 2022
- Revisit PMP Company Criteria to Support Innovation from Foreign Biotechs: Experts
December 12, 2022
- Experts Call for New Drug Pricing Rule for Innovative Medicines, No Objections Raised
December 12, 2022
- 70% of Listed Meds Likely to Face Off-Year Re-Pricing If Prior Threshold Applied: MHLW
December 12, 2022
- Keytruda Gets Orphan Tag for PMBCL in Japan
December 12, 2022
- First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
- Panel OKs Moderna Boosters for Age 12 and Up
December 9, 2022
- Industry Prods Special Inflation Measure in Off Year, Payers Don’t See Much Need: Chuikyo Hearing
December 8, 2022
- Japan Offers Mpox Vaccines to Columbia for Free
December 8, 2022
- Man Sues PMDA over Rejected Relief Claim for “Ranitidine Caused Cancer”
December 7, 2022
- Lilly’s Insulin Lyumjev Gets Label Update for Pediatric Use
December 7, 2022
- Delete Contraindications on Use of Amlodipine, Nifedipine in Pregnant Women: MHLW
December 6, 2022
- Susmed’s Insomnia App Up for PAFSC Review on December 19
December 6, 2022
- PAFSC Committee OKs Plan to Monitor Early Safety Signals from Xocova Using MID-NET
December 5, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…